drugset / Trial / NCT01885182

Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain

NCT01885182

Phase 3 Completed 232 enrolled Mundipharma (China) Pharmaceutical Co. Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain

Timeline

Start
2013-06-01
Primary completion
2015-08-30
Completion
2015-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 2.5 mg
Subject Naloxone Small molecule 5 mg
Subject Naloxone Small molecule 10 mg
Subject Naloxone Small molecule 20 mg
Subject Oxycodone Other / unclassified 5 mg
Subject Oxycodone Other / unclassified 10 mg
Subject Oxycodone Other / unclassified 20 mg
Subject Oxycodone Other / unclassified 40 mg

Indications